NL
DE
Werner Koopman, theme Metabolic Diseases, received 250K Euro as a member of the CureMILS consortium. The latter is funded by the European Joint Programme on Rare Diseases (EJP-RD), which brings together over 130 institutions from 35 countries and focuses on pre-clinical research to develop effective therapies for rare diseases.
The project will run for three years, receiving a total of 2.4 million Euro in funding, and will apply a cell-based reprogramming strategy for drug repositioning in patients with mitochondrial DNA-associated Leigh Syndrome.
CureMILS involves eight academic partners from Germany (Heinrich Heine University, Duesseldorf; Fraunhofer IME, Hamburg), Austria (Innsbruck University), The Netherlands (Radboudumc), Finland (University of Helsinki), Poland (Institute of Genetics and Animal Biotechnology, Jastrzebiec), Italy (Verona University) and Luxemburg (University of Luxembourg). Other participants include various collaborators (Germany, Austria and Italy) and a patient organization (International Mito Patients; IMP).
At Radboudumc, CureMILS will be carried out in a collaborative effort between the groups of Werner Koopman and Nael Nadif Kasri.
Related news items
New genetic defect links cell biology and protein glycosylation
10 November 2021 Peter Linders, Dirk Lefeber and Geert van den Bogaart together with international colleagues have recently reported on novel cell biological insights, by identifying a genetic disorder in syntaxin-5 which allowed to unravel a new mechanism regulating intracellular transportation. read more
Newborn screening in sight through the discovery of novel disease biomarkers by new technique
8 July 2021New biomarkers that can be used in the newborn screening protocol, also known as the neonatal heel prick, Karlien Coene and colleagues joined forces with scientists at the Radboud University’s FELIX laser laboratory. They published their findings in The Journal of Clinical Investigation.
read more
Miniaturized microfluidic platform for automated epigenetic profiling
6 May 2021 Together with Fluidigm, a US-based company focusing on microfluidics, the team of Hendrik Marks publishes in Genome Research the development of a powerful plug and play ChIP-seq platform for minute amount of cells, such as embryonic specimens or small biopsies. read more
New way of diagnostics detects 'undetectable' genetic defects
15 April 2021Research provides guidance for global application
read more
